Follow
Christopher E.M. Griffiths
Christopher E.M. Griffiths
Professor of Dermatology, University of Manchester
Verified email at manchester.ac.uk
Title
Cited by
Cited by
Year
Pathogenesis and clinical features of psoriasis
CEM Griffiths, JNWN Barker
The Lancet 370 (9583), 263-271, 2007
26332007
Global epidemiology of psoriasis: a systematic review of incidence and prevalence
R Parisi, DPM Symmons, CEM Griffiths, DM Ashcroft
Journal of Investigative Dermatology 133 (2), 377-385, 2013
23852013
Secukinumab in plaque psoriasis—results of two phase 3 trials
RG Langley, BE Elewski, M Lebwohl, K Reich, CEM Griffiths, K Papp, ...
New England Journal of Medicine 371 (4), 326-338, 2014
22032014
Real-world experience of patient-relevant benefits and treatment satisfaction with apremilast in patients with psoriasis: an analysis of the APPRECIATE study
TM Klein, C Blome, CE Kleyn, C Conrad, PG Sator, M Ståhle, K Eyerich, ...
Dermatology and Therapy 12 (1), 81-95, 2022
19302022
Psoriasis: epidemiology, clinical features, and quality of life
RGB Langley, GG Krueger, CEM Griffiths
Annals of the rheumatic diseases 64 (suppl 2), ii18-ii23, 2005
14292005
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich, FO Nestle, K Papp, JP Ortonne, R Evans, C Guzzo, S Li, ...
The Lancet 366 (9494), 1367-1374, 2005
13072005
Rook's textbook of dermatology
T Burns, SM Breathnach, N Cox, C Griffiths
John Wiley & Sons, 2008
12202008
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded …
A Blauvelt, M de Bruin-Weller, M Gooderham, JC Cather, J Weisman, ...
The Lancet 389 (10086), 2287-2303, 2017
11502017
Definition of treatment goals for moderate to severe psoriasis: a European consensus
U Mrowietz, K Kragballe, K Reich, P Spuls, CEM Griffiths, A Nast, J Franke, ...
Archives of dermatological research 303, 1-10, 2011
10822011
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
LC Tsoi, SL Spain, J Knight, E Ellinghaus, PE Stuart, F Capon, J Ding, ...
Nature genetics 44 (12), 1341-1348, 2012
10452012
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis
CEM Griffiths, BE Strober, P Van De Kerkhof, V Ho, R Fidelus-Gort, ...
New England Journal of Medicine 362 (2), 118-128, 2010
10272010
Genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
A Strange, F Capon, CCA Spencer, J Knight, ME Weale, MH Allen, ...
Nature genetics 42 (11), 985, 2010
10142010
Keratinocytes as initiators of inflammation
JNWN Barker, CEM Griffiths, BJ Nickoloff, RS Mitra, VM Dixit
The Lancet 337 (8735), 211-214, 1991
9561991
European S3-guidelines on the systemic treatment of psoriasis vulgaris
D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, ...
Journal of the European Academy of Dermatology and Venereology 23 (SUPPL. 2 …, 2009
9552009
Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence
R Parisi, DP Symmons, CE Griffiths, DM Ashcroft
J Invest Dermatol 133 (2), 377-385, 2013
8722013
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
CEM Griffiths, K Reich, M Lebwohl, P Van De Kerkhof, C Paul, A Menter, ...
The Lancet 386 (9993), 541-551, 2015
8622015
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe …
A Blauvelt, KA Papp, CEM Griffiths, B Randazzo, Y Wasfi, YK Shen, S Li, ...
Journal of the american academy of dermatology 76 (3), 405-417, 2017
8602017
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp, S Tyring, M Lahfa, J Prinz, CEM Griffiths, AM Nakanishi, R Zitnik, ...
British Journal of Dermatology 152 (6), 1304-1312, 2005
8552005
Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial
TN Brooklyn, MGS Dunnill, A Shetty, JJ Bowden, JDL Williams, ...
Gut 55 (4), 505-509, 2006
7552006
Rook's textbook of dermatology
CEM Griffiths, J Barker, TO Bleiker, R Chalmers, D Creamer
John Wiley & Sons, 2016
714*2016
The system can't perform the operation now. Try again later.
Articles 1–20